Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection
Open Access
- 26 May 2023
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-9
Abstract
Binding antibody levels against SARS-CoV-2 have shown to be correlates of protection against infection with pre-Omicron lineages. This has been challenged by the emergence of immune-evasive variants, notably the Omicron sublineages, in an evolving immune landscape with high levels of cumulative incidence and vaccination coverage. This in turn limits the use of widely available commercial high-throughput methods to quantify binding antibodies as a tool to monitor protection at the population-level. Here we show that anti-Spike RBD antibody levels, as quantified by the immunoassay used in this study, are an indirect correlate of protection against Omicron BA.1/BA.2 for individuals previously infected by SARS-CoV-2. Leveraging repeated serological measurements between April 2020 and December 2021 on 1083 participants of a population-based cohort in Geneva, Switzerland, and using antibody kinetic modeling, we found up to a three-fold reduction in the hazard of having a documented positive SARS-CoV-2 infection during the Omicron BA.1/BA.2 wave for anti-S antibody levels above 800 IU/mL (HR 0.30, 95% CI 0.22-0.41). However, we did not detect a reduction in hazard among uninfected participants. These results provide reassuring insights into the continued interpretation of SARS-CoV-2 binding antibody measurements as an independent marker of protection at both the individual and population levels.Keywords
Funding Information
- Private Foundation of the Geneva University Hospitals General Directorate of Health of the canton of Geneva
This publication has 36 references indexed in Scilit:
- Evidence for antibody as a protective correlate for COVID-19 vaccinesVaccine, 2021
- Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, SwitzerlandNature Communications, 2021
- Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humansCell Host & Microbe, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peakThe Lancet Infectious Diseases, 2021
- Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal studyClinical Microbiology and Infection, 2021
- Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Avidity Maturation and Association with Disease SeverityClinical Infectious Diseases, 2020
- Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based studyThe Lancet, 2020
- The Role of Antibody Testing for SARS-CoV-2: Is There One?Journal of Clinical Microbiology, 2020
- ipw: AnRPackage for Inverse Probability WeightingJournal of Statistical Software, 2011